Therapeutic Monitoring and Prediction of the Efficacy of Neurotrophic Therapy in Patients with Amnestic-Type Mild Cognitive Decline Syndrome

Abstract

Objectives. Therapeutic monitoring and evaluation of the efficacy of neurotrophic therapy in patients with amnestic-type mild cognitive decline syndrome (aMCI) were performed in a model using courses of cerebrolysin. Materials and methods. A total of 19 elderly patients meeting the diagnostic criteria for aMCI syndrome were studied. All patients received treatment with cerebrolysin: 20 intravenous dropwise infusions of 30 ml in 100 ml of physiological saline. Treatment efficacy was evaluated using psychometric tests and scales (CGI, MMSE, MoCA, MDRS, clock drawing test, BNT, 10-word memory test, 10-word delayed reproduction test, forward number naming test, backward number naming test) at study weeks 0, 4, 10, and 26. Levels of autoantibodies to p75 neurotrophin receptor were determined by solid-phase immnoenzyme analysis. Serum from 19 patients was studied before cerebrolysin treatment (day 0) and at weeks 10 and 26 after treatment initiation. Results and conclusions. Patients with aMCI had increased levels of autoantibodies to p75 fragment, with gradual decreases by 5.5 months of cerebrolysin treatment, indicating that this can potentially be used as a biomarker for long-term therapeutic efficacy. The modified p75 receptor fragment 155–164, assayed in patients’ serum, may provide an effective tool for monitoring and predicting the efficacy of long-term neurotrophic therapy.